Pulmonary arterial hypertension (PAH) remains one of the most challenging entities in cardiovascular and pulmonary medicine. It is rare, progressive, and, if left untreated, relentlessly fatal. Yet over the past three decades, the therapeutic landscape has transformed from therapeutic nihilism to structured, pathway-targeted, and increasingly aggressive pharmacotherapy. Contemporary registry data from Japan provide a particularly […]